176 related articles for article (PubMed ID: 12499244)
1. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
3. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
[TBL] [Abstract][Full Text] [Related]
4. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
5. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
6. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
Gorelik L; Flavell RA
Nat Med; 2001 Oct; 7(10):1118-22. PubMed ID: 11590434
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice.
Davidoff AM; Ng CY; Brown P; Leary MA; Spurbeck WW; Zhou J; Horwitz E; Vanin EF; Nienhuis AW
Clin Cancer Res; 2001 Sep; 7(9):2870-9. PubMed ID: 11555605
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
Akiyama Y; Watanabe M; Maruyama K; Ruscetti FW; Wiltrout RH; Yamaguchi K
Gene Ther; 2000 Dec; 7(24):2113-21. PubMed ID: 11223993
[TBL] [Abstract][Full Text] [Related]
9. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
Tang B; de Castro K; Barnes HE; Parks WT; Stewart L; Böttinger EP; Danielpour D; Wakefield LM
Cancer Res; 1999 Oct; 59(19):4834-42. PubMed ID: 10519393
[TBL] [Abstract][Full Text] [Related]
10. Effect of dominant negative transforming growth factor-beta receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line.
Lee GT; Hong JH; Kwak C; Woo J; Liu V; Lee C; Kim IY
Cancer Res; 2007 Jul; 67(14):6717-24. PubMed ID: 17638882
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Yang F; Strand DW; Rowley DR
Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
[TBL] [Abstract][Full Text] [Related]
12. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.
Bandyopadhyay A; Zhu Y; Cibull ML; Bao L; Chen C; Sun L
Cancer Res; 1999 Oct; 59(19):5041-6. PubMed ID: 10519421
[TBL] [Abstract][Full Text] [Related]
13. Quiescence of hematopoietic stem cells and maintenance of the stem cell pool is not dependent on TGF-beta signaling in vivo.
Larsson J; Blank U; Klintman J; Magnusson M; Karlsson S
Exp Hematol; 2005 May; 33(5):592-6. PubMed ID: 15850837
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Song K; Cornelius SC; Danielpour D
Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of TGF-beta activity during retroviral transduction improves murine hematopoietic progenitor and repopulating cell gene transfer efficiency.
Yu J; Soma T; Hanazono Y; Dunbar CE
Gene Ther; 1998 Sep; 5(9):1265-71. PubMed ID: 9930329
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice.
Tian F; Wang L; Qin W; Wang F; Song B; Li Y; Wen W; Zhang Z; Zhu K; Zhang Q; Lee C; Zhong W; Guo Y; Wang H
Cancer Lett; 2008 Nov; 271(2):333-41. PubMed ID: 18675506
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
[TBL] [Abstract][Full Text] [Related]
18. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis.
Gautam A; Densmore CL; Melton S; Golunski E; Waldrep JC
Cancer Gene Ther; 2002 Jan; 9(1):28-36. PubMed ID: 11916242
[TBL] [Abstract][Full Text] [Related]
19. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
